U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07158229) titled 'Long-term Impact of NMDAR Encephalitis, Level 3' on Aug. 28.
Brief Summary: NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored.
C...